Skip to content

The Mechanisms of Tailored Immunotherapy of Yiqihuoxuejiedu Formula Modulating Regulatory T Cells at Level of Inherited Single Nucleotide Polymorphisms in Advanced Ovarian

The Mechanisms of Tailored Immunotherapy of Yiqihuoxuejiedu Formula Modulating Regulatory T Cells at Level of Inherited Single Nucleotide Polymorphisms in Advanced Ovarian

Status
Recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPC-15005981
Enrollment
Unknown
Registered
2015-01-31
Start date
2015-02-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The advanced ovarian cancer

Interventions

Greater than the median progression-free survival :Yiqihuoxuejiedu Formula
Less than or equal to the median progression-free:Yiqihuoxuejiedu Formula

Sponsors

Guang'anmen Hospital China Academy of Chinese medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The age of 18 years old or more, or less at the age of 80; 2. IIIC and IV ovarian cancer (pathologic staging need level 3 first-class hospital gynecologic tumor pathology experts determine); 3. Reduce tumor does not exceed six months postoperatively, system chemotherapy ended more than a month; 4. Adjuvant chemotherapy for 6-8 cycles of platinum + yew solutions of a class, curative effect evaluation according to the WHO standards; 5. Patients need to qi deficiency blood stasis syndrome differentiation type, standard reference the Chinese traditional medicine new drug clinical research guiding principles (try out)", under the guidance of TCM, director of the physician to complete; 6. Karnofsky score 70 points or more.

Exclusion criteria

Exclusion criteria: 1. The original heart, liver, kidney and hematopoietic system, such as serious illness; 2. Accompanied by mental illness, severe neurologic deficits (such as aphasia, agnosia), or for other reasons can't cooperate with the investigators; 3. Recent use of immunosuppressants; 4. this study drug ingredients known allergies; 5. Age less than 18 years of age or older than 80 years old.

Design outcomes

Primary

MeasureTime frame
Progress free survival;SNPs site differences;The expression of mRNA;

Countries

China

Contacts

Public ContactWenping Lu
lu_wenping@sina.com+86 13811210423

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026